Cryosite Limited (ASX:CTE)

Market Cap	39.05M
Revenue (ttm)	14.12M
Net Income (ttm)	1.88M
Shares Out	48.81M
EPS (ttm)	0.04
PE Ratio	21.16
Forward PE	n/a
Dividend	0.02 (2.50%)
Ex-Dividend Date	Sep 6, 2024

Volume	3,911
Average Volume	3,875
Open	0.8000
Previous Close	0.8000
Day's Range	0.8000 - 0.8000
52-Week Range	0.6600 - 0.9500
Beta	0.30
RSI	68.95
Earnings Date	Aug 22, 2025

About Cryosite

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen, Ultra-frozen and cryogenic, and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 25
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CTE

Financial Performance

In 2025, Cryosite's revenue was 14.12 million, an increase of 11.93% compared to the previous year's 12.61 million. Earnings were 1.88 million, an increase of 2.39%.